JP2018524362A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018524362A5 JP2018524362A5 JP2018500881A JP2018500881A JP2018524362A5 JP 2018524362 A5 JP2018524362 A5 JP 2018524362A5 JP 2018500881 A JP2018500881 A JP 2018500881A JP 2018500881 A JP2018500881 A JP 2018500881A JP 2018524362 A5 JP2018524362 A5 JP 2018524362A5
- Authority
- JP
- Japan
- Prior art keywords
- active agent
- administration
- treatment
- disease
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003795 chemical substances by application Substances 0.000 claims 21
- 230000035492 administration Effects 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 102000004965 antibodies Human genes 0.000 claims 6
- 108090001123 antibodies Proteins 0.000 claims 6
- 210000003169 Central Nervous System Anatomy 0.000 claims 4
- 102100016020 IFNG Human genes 0.000 claims 4
- 101700086956 IFNG Proteins 0.000 claims 4
- 210000000265 Leukocytes Anatomy 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 206010062016 Immunosuppression Diseases 0.000 claims 3
- 230000001506 immunosuppresive Effects 0.000 claims 3
- 206010022114 Injury Diseases 0.000 claims 2
- 206010053643 Neurodegenerative disease Diseases 0.000 claims 2
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims 2
- 230000003920 cognitive function Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 150000003384 small molecules Chemical class 0.000 claims 2
- 206010064930 Age-related macular degeneration Diseases 0.000 claims 1
- 206010001897 Alzheimer's disease Diseases 0.000 claims 1
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 229920002395 Aptamer Polymers 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 210000004227 Basal Ganglia Anatomy 0.000 claims 1
- 210000004369 Blood Anatomy 0.000 claims 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 1
- -1 CD27-CD70 Proteins 0.000 claims 1
- 101700015421 CD276 Proteins 0.000 claims 1
- 102100019456 CD276 Human genes 0.000 claims 1
- 206010057668 Cognitive disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 102000016680 Dioxygenases Human genes 0.000 claims 1
- 108010028143 Dioxygenases Proteins 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 102100002135 HHLA2 Human genes 0.000 claims 1
- 101700086312 HHLA2 Proteins 0.000 claims 1
- 102000015434 Humanized Monoclonal Antibodies Human genes 0.000 claims 1
- 108010064750 Humanized Monoclonal Antibodies Proteins 0.000 claims 1
- 201000001971 Huntington's disease Diseases 0.000 claims 1
- 210000000987 Immune System Anatomy 0.000 claims 1
- 102000018358 Immunoglobulins Human genes 0.000 claims 1
- 108060003951 Immunoglobulins Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 102100014726 MECP2 Human genes 0.000 claims 1
- 101700029603 MECP2 Proteins 0.000 claims 1
- 208000002780 Macular Degeneration Diseases 0.000 claims 1
- 102000004473 OX40 Ligand Human genes 0.000 claims 1
- 108010042215 OX40 Ligand Proteins 0.000 claims 1
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 claims 1
- 206010061536 Parkinson's disease Diseases 0.000 claims 1
- 208000001282 Primary Progressive Aphasia Diseases 0.000 claims 1
- 206010063401 Primary progressive multiple sclerosis Diseases 0.000 claims 1
- 208000007014 Retinitis Pigmentosa Diseases 0.000 claims 1
- 208000006289 Rett Syndrome Diseases 0.000 claims 1
- 108010070144 Single-Chain Antibodies Proteins 0.000 claims 1
- 102000005632 Single-Chain Antibodies Human genes 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 206010042211 Stress disease Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 101710036075 VSIR Proteins 0.000 claims 1
- 102100015314 VSIR Human genes 0.000 claims 1
- 101700068327 VTCN1 Proteins 0.000 claims 1
- 102100014952 VTCN1 Human genes 0.000 claims 1
- 239000002598 adenosine A1 receptor antagonist Substances 0.000 claims 1
- 239000002467 adenosine A2a receptor antagonist Substances 0.000 claims 1
- 230000000240 adjuvant Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 229930002945 all-trans-retinaldehyde Natural products 0.000 claims 1
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 230000000903 blocking Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 230000020411 cell activation Effects 0.000 claims 1
- 210000004027 cells Anatomy 0.000 claims 1
- 230000001054 cortical Effects 0.000 claims 1
- 230000003412 degenerative Effects 0.000 claims 1
- 210000003162 effector T lymphocyte Anatomy 0.000 claims 1
- 201000011240 frontotemporal dementia Diseases 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 230000013016 learning Effects 0.000 claims 1
- 230000015654 memory Effects 0.000 claims 1
- 230000003340 mental Effects 0.000 claims 1
- 230000003278 mimic Effects 0.000 claims 1
- 230000002314 neuroinflammatory Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 230000002207 retinal Effects 0.000 claims 1
- 235000020945 retinal Nutrition 0.000 claims 1
- 239000011604 retinal Substances 0.000 claims 1
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 claims 1
- 230000004936 stimulating Effects 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021065556A JP2021107412A (ja) | 2014-03-12 | 2021-04-08 | Ｃｎｓの疾患および損傷を処置するための全身における制御性ｔ細胞のレベルまたは活性の低下 |
| JP2023064537A JP2023089119A (ja) | 2014-03-12 | 2023-04-12 | Ｃｎｓの疾患および損傷を処置するための全身における制御性ｔ細胞のレベルまたは活性の低下 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461951783P | 2014-03-12 | 2014-03-12 | |
| US201462030164P | 2014-07-29 | 2014-07-29 | |
| US14/797,894 US9856318B2 (en) | 2014-03-12 | 2015-07-13 | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| US14/797,894 | 2015-07-13 | ||
| PCT/IL2016/050750 WO2017009829A1 (en) | 2014-03-12 | 2016-07-13 | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021065556A Division JP2021107412A (ja) | 2014-03-12 | 2021-04-08 | Ｃｎｓの疾患および損傷を処置するための全身における制御性ｔ細胞のレベルまたは活性の低下 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018524362A JP2018524362A (ja) | 2018-08-30 |
| JP2018524362A5 true JP2018524362A5 (lt) | 2019-08-15 |
| JP6867367B2 JP6867367B2 (ja) | 2021-04-28 |
Family
ID=53488381
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016556895A Active JP6903432B2 (ja) | 2014-03-12 | 2015-03-12 | Ｃｎｓの疾患および傷害を処置するために全身性調節性ｔ細胞のレベルまたは活性を低下させること |
| JP2018500881A Active JP6867367B2 (ja) | 2014-03-12 | 2016-07-13 | Ｃｎｓの疾患および損傷を処置するための全身における制御性ｔ細胞のレベルまたは活性の低下 |
| JP2019210982A Pending JP2020040976A (ja) | 2014-03-12 | 2019-11-22 | Ｃｎｓの疾患および傷害を処置するために全身性調節性ｔ細胞のレベルまたは活性を低下させること |
| JP2021065556A Pending JP2021107412A (ja) | 2014-03-12 | 2021-04-08 | Ｃｎｓの疾患および損傷を処置するための全身における制御性ｔ細胞のレベルまたは活性の低下 |
| JP2022115925A Pending JP2022163730A (ja) | 2014-03-12 | 2022-07-20 | Ｃｎｓの疾患および傷害を処置するために全身性調節性ｔ細胞のレベルまたは活性を低下させること |
| JP2023064537A Pending JP2023089119A (ja) | 2014-03-12 | 2023-04-12 | Ｃｎｓの疾患および損傷を処置するための全身における制御性ｔ細胞のレベルまたは活性の低下 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016556895A Active JP6903432B2 (ja) | 2014-03-12 | 2015-03-12 | Ｃｎｓの疾患および傷害を処置するために全身性調節性ｔ細胞のレベルまたは活性を低下させること |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019210982A Pending JP2020040976A (ja) | 2014-03-12 | 2019-11-22 | Ｃｎｓの疾患および傷害を処置するために全身性調節性ｔ細胞のレベルまたは活性を低下させること |
| JP2021065556A Pending JP2021107412A (ja) | 2014-03-12 | 2021-04-08 | Ｃｎｓの疾患および損傷を処置するための全身における制御性ｔ細胞のレベルまたは活性の低下 |
| JP2022115925A Pending JP2022163730A (ja) | 2014-03-12 | 2022-07-20 | Ｃｎｓの疾患および傷害を処置するために全身性調節性ｔ細胞のレベルまたは活性を低下させること |
| JP2023064537A Pending JP2023089119A (ja) | 2014-03-12 | 2023-04-12 | Ｃｎｓの疾患および損傷を処置するための全身における制御性ｔ細胞のレベルまたは活性の低下 |
Country Status (13)
| Country | Link |
|---|---|
| US (16) | US10144778B2 (lt) |
| EP (1) | EP3116542A2 (lt) |
| JP (6) | JP6903432B2 (lt) |
| KR (4) | KR102248804B1 (lt) |
| CN (2) | CN106687125B (lt) |
| AU (5) | AU2015228372B2 (lt) |
| BR (2) | BR112016020919A2 (lt) |
| CA (3) | CA3129892A1 (lt) |
| IL (2) | IL256792B2 (lt) |
| MX (3) | MX2016011832A (lt) |
| NZ (2) | NZ725006A (lt) |
| RU (2) | RU2690670C2 (lt) |
| WO (2) | WO2015136541A2 (lt) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240093808A (ko) | 2008-12-09 | 2024-06-24 | 제넨테크, 인크. | 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도 |
| CA2932966C (en) | 2013-12-12 | 2022-03-22 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Pd-1 antibody, antigen-binding fragment thereof, and medical use thereof |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| WO2017042633A2 (en) * | 2015-09-10 | 2017-03-16 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
| US9394365B1 (en) * | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
| US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| JP6903432B2 (ja) | 2014-03-12 | 2021-07-14 | イエダ リサーチ アンド ディベロップメント カンパニー リミテッド | Ｃｎｓの疾患および傷害を処置するために全身性調節性ｔ細胞のレベルまたは活性を低下させること |
| US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| CA2984975A1 (en) | 2015-05-06 | 2016-11-10 | Snipr Technologies Limited | Altering microbial populations & modifying microbiota |
| WO2016179517A1 (en) | 2015-05-07 | 2016-11-10 | Agenus Inc. | Anti-ox40 antibodies and methods of use thereof |
| TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| PH12018500269B1 (en) | 2015-08-07 | 2023-10-20 | Alx Oncology Inc | Constructs having a sirp-alpha domain or variant thereof |
| KR101785155B1 (ko) * | 2015-09-22 | 2017-10-16 | 국립암센터 | Ｔｉｍ－３을 표적으로 하는 뇌손상 질환 치료용 조성물 및 이의 스크리닝 방법 |
| BR112018006237A2 (pt) | 2015-09-29 | 2018-10-09 | Celgene Corp | proteínas de ligação a pd-1 e métodos de uso das mesmas |
| MX2018006477A (es) | 2015-12-02 | 2018-09-03 | Agenus Inc | Anticuerpos y metodos de uso de estos. |
| MX2018008350A (es) | 2016-01-08 | 2019-05-30 | Arcus Biosciences Inc | Moduladores de 5´-nucleotidasa, ecto y el uso de los mismos. |
| US12128102B2 (en) | 2016-03-08 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| MD3443009T2 (ro) | 2016-04-12 | 2022-02-28 | Symphogen As | Anticorpi anti-TIM-3 și compoziții |
| SG10201912563XA (en) | 2016-05-27 | 2020-02-27 | Agenus Inc | Anti-tim-3 antibodies and methods of use thereof |
| GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
| CA3026477A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 antibodies |
| WO2018029474A2 (en) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| TWI689514B (zh) | 2016-07-06 | 2020-04-01 | 美商史貝羅威生物科學有限公司 | 化合物、組合物及用於治療疾病之方法 |
| TWI760352B (zh) | 2016-08-09 | 2022-04-11 | 英商克馬伯有限公司 | 抗ｉｃｏｓ抗體 |
| CN116492457A (zh) * | 2016-09-10 | 2023-07-28 | 耶达研究与开发有限公司 | 降低全身调节性t细胞水平或活性以治疗中枢神经系统的疾病和损伤 |
| WO2018050902A2 (en) | 2016-09-15 | 2018-03-22 | Quadrucept Bio Limited | Multimers, tetramers & octamers |
| CN109952317A (zh) | 2016-09-19 | 2019-06-28 | 细胞基因公司 | 使用pd-1结合蛋白治疗免疫病症的方法 |
| JP2019534859A (ja) | 2016-09-19 | 2019-12-05 | セルジーン コーポレイション | Ｐｄ−１結合タンパク質を使用して白斑を治療する方法 |
| EP3526256A1 (en) | 2016-10-11 | 2019-08-21 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
| ES2930099T3 (es) | 2016-11-01 | 2022-12-05 | Univ Osaka | Agente anticancerígeno que comprende HVJ-E y un anticuerpo neutralizante contra PD-1 |
| WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| MA46770A (fr) | 2016-11-09 | 2019-09-18 | Agenus Inc | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation |
| AU2017368155B2 (en) | 2016-11-30 | 2022-02-24 | Oncomed Pharmaceuticals, Inc. | Methods for treatment of cancer comprising TIGIT-binding agents |
| KR102236038B1 (ko) * | 2016-12-06 | 2021-04-05 | 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 | 신규 프리오노이드병용 치료약 |
| WO2018185232A1 (en) | 2017-04-05 | 2018-10-11 | Symphogen A/S | Combination therapies targeting pd-1, tim-3, and lag-3 |
| MA50956A (fr) | 2017-04-13 | 2020-10-14 | Agenus Inc | Anticorps anti-cd137 et procédés d'utilisation correspondants |
| LT3618863T (lt) | 2017-05-01 | 2023-10-10 | Agenus Inc. | Anti-tigit antikūnai ir jų panaudojimo būdai |
| GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| TWI828626B (zh) * | 2017-06-30 | 2024-01-11 | 日商小野藥品工業股份有限公司 | 併用包含溶血性鏈球菌之菌體的製劑的療法 |
| EP3675859A4 (en) | 2017-08-31 | 2021-06-30 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND PROCEDURES FOR TREATMENT OF DISEASES |
| US11584774B2 (en) | 2017-09-11 | 2023-02-21 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
| WO2019051489A1 (en) | 2017-09-11 | 2019-03-14 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE |
| EP3456819A1 (en) * | 2017-09-13 | 2019-03-20 | Trizell GmbH | Regulatory macrophages for the treatment of angopathies |
| US20190160120A1 (en) | 2017-11-29 | 2019-05-30 | Snipr Biome Aps | Dna, methods etc |
| WO2019122882A1 (en) | 2017-12-19 | 2019-06-27 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
| CN112292145A (zh) | 2018-03-25 | 2021-01-29 | 斯尼普生物群系有限公司 | 治疗和预防微生物感染 |
| WO2019186559A1 (en) * | 2018-03-27 | 2019-10-03 | Raz Yirmiya | Microglia modulators for use in treatment of depression |
| US11851663B2 (en) | 2018-10-14 | 2023-12-26 | Snipr Biome Aps | Single-vector type I vectors |
| CN109453383A (zh) * | 2018-11-12 | 2019-03-12 | 陈慧慧 | 免疫检查点的抑制剂在制备治疗青光眼及其他眼部免疫损伤机制相关疾病药物中的应用 |
| EP3911954A4 (en) * | 2019-01-16 | 2022-11-02 | Yeda Research and Development Co. Ltd | BIOMARKERS FOR MODIFICATION OF CNS DISEASES |
| GB201901099D0 (en) | 2019-01-27 | 2019-03-13 | Snipr Biome Aps | Methods, uses and compositions |
| GB201903767D0 (en) | 2019-03-19 | 2019-05-01 | Quadrucept Bio Ltd | Multimers, tetramers & octamers |
| EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
| GB201906668D0 (en) | 2019-05-12 | 2019-06-26 | Folium Food Science Ltd | Antibacterial agents |
| GB201907242D0 (en) | 2019-05-22 | 2019-07-03 | Snipr Biome Aps | Dna methods etc ii |
| AU2020282791A1 (en) | 2019-05-31 | 2021-12-09 | ALX Oncology Inc. | Methods of treating cancer with SIRP alpha Fc fusion in combination with an immune checkpoint inhibitor |
| GB201912176D0 (en) | 2019-08-23 | 2019-10-09 | Snipr Biome Aps | Plasmids |
| WO2021098750A1 (en) * | 2019-11-21 | 2021-05-27 | Beigene (Beijing) Co., Ltd. | Methods of cancer treatment with anti-ox40 antibody in comibinaiton with tlr agonists |
| US11633416B1 (en) | 2020-03-06 | 2023-04-25 | Arcus Biosciences, Inc. | Oral formulations of CD73 compounds |
| WO2021190980A1 (en) | 2020-03-22 | 2021-09-30 | Quadrucept Bio Limited | Multimers for viral strain evolution |
| GB202007943D0 (en) | 2020-05-27 | 2020-07-08 | Snipr Biome Aps | Products & methods |
| GB202015255D0 (en) | 2020-09-26 | 2020-11-11 | Snipr Biome Aps | Synthetic viruses |
| GB202017618D0 (en) | 2020-11-08 | 2020-12-23 | Folium Food Science Ltd | Antibacterial methods & cells |
| BR112023015652A2 (pt) | 2021-02-04 | 2023-10-17 | Genuv Inc | Anticorpo ou fragmento de ligação a antígeno do mesmo que se liga a um epítopo de uma proteína de morte celular programada 1 (pd-1); molécula de ácido nucleico; vetor de clonagem ou de expressão; célula hospedeira; método para produzir o anticorpo ou fragmento de ligação a antígeno do mesmo; animal transgênico; molécula de ligação a antígeno multiespecífico, imunoconjugado, receptor de antígeno quimérico, receptor de célula t modificado ou vírus oncolítico; composição farmacêutica para prevenir ou tratar uma afecção associada a pd-1; método para prevenir ou tratar tumores, doenças autoimunes de câncer, doenças autoimunes, doenças neurológicas, doenças neurodegenerativas ou doenças infecciosas; composição farmacêutica para aumentar uma resposta imunológica em um indivíduo que tem câncer; e hibridoma |
| WO2022184659A1 (en) | 2021-03-01 | 2022-09-09 | Quadrucept Bio Limited | Antibody domains & multimers |
| TW202304965A (zh) | 2021-05-04 | 2023-02-01 | 美商艾吉納斯公司 | 抗ｔｉｇｉｔ抗體、抗ｃｄ９６抗體及其使用方法 |
| US12098214B2 (en) | 2021-05-13 | 2024-09-24 | ALX Oncology Inc. | Combination therapies for treating cancer |
| US20220396623A1 (en) | 2021-05-18 | 2022-12-15 | Kymab Limited | Uses of anti-icos antibodies |
| EP4422752A1 (en) * | 2021-10-28 | 2024-09-04 | Baylor College of Medicine | Targeting neuronal sirpa for treatment and prevention of neurological disorders |
| FR3136481A1 (fr) | 2021-12-17 | 2023-12-15 | Snipr Biome Aps | Procedes et compositions d'apport d'acide nucleique |
| CN114984219B (zh) * | 2022-03-29 | 2023-06-27 | 浙江大学 | Pd1抑制剂在制备心脏成纤维细胞转分化抑制剂中的用途 |
| WO2023222854A1 (en) | 2022-05-18 | 2023-11-23 | Kymab Limited | Uses of anti-icos antibodies |
| GB202209518D0 (en) | 2022-06-29 | 2022-08-10 | Snipr Biome Aps | Treating & preventing E coli infections |
| GB202212688D0 (en) | 2022-08-31 | 2022-10-12 | Snipr Biome Aps | A novel type of crispr/cas system |
| GB202216503D0 (en) | 2022-11-05 | 2022-12-21 | Quadrucept Bio Ltd | Non-human vertebrates & cells |
Family Cites Families (122)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL36670A (en) | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| IL113812A (en) | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
| WO2000005250A1 (en) | 1998-07-23 | 2000-02-03 | Yeda Research And Development Co., Ltd | Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides |
| WO2000005249A2 (en) | 1998-07-23 | 2000-02-03 | The President And Fellows Of Harvard College | Synthetic peptides and methods of use for autoimmune disease therapies |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| ES2248283T3 (es) * | 2000-02-21 | 2006-03-16 | Pharmexa A/S | Nuevo procedimiento para reducir los niveles de amiloide. |
| US20040033497A1 (en) * | 2002-08-13 | 2004-02-19 | Alarcon-Riquelme Marta E. | Polymorphisms of PD-1 |
| US7981863B2 (en) * | 2001-09-19 | 2011-07-19 | Neuronova Ab | Treatment of Parkinson's disease with PDGF |
| EP1438061B1 (en) | 2001-10-03 | 2016-05-11 | President and Fellows of Harvard College | Copolymers for suppression of autoimmune diseases, and methods of use |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| EP2243493A1 (en) | 2002-07-03 | 2010-10-27 | Ono Pharmaceutical Co., Ltd. | Immunopotentiative composition |
| ES2729974T3 (es) | 2003-01-23 | 2019-11-07 | Ono Pharmaceutical Co | Anticuerpo específico de PD-1 y CD3 humanas |
| CA2541006C (en) * | 2003-10-03 | 2015-02-17 | Brigham And Women's Hospital | Tim-3 polypeptides |
| EP2248830A1 (en) | 2003-11-04 | 2010-11-10 | Novartis Vaccines and Diagnostics, Inc. | Use of antagonist anti-CD40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection |
| EP1684797A1 (en) * | 2003-11-12 | 2006-08-02 | Yeda Research and Development Co. Ltd. | Vaccine and method for treatment of neurodegenerative diseases |
| GB0400440D0 (en) | 2004-01-09 | 2004-02-11 | Isis Innovation | Receptor modulators |
| CA2568344C (en) | 2004-05-27 | 2016-01-19 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
| GB0503434D0 (en) * | 2005-02-18 | 2005-03-30 | Senexis Ltd | Amyloid-binding peptides, analogues and uses thereof |
| CN117534755A (zh) | 2005-05-09 | 2024-02-09 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| KR101607288B1 (ko) * | 2005-07-01 | 2016-04-05 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| JP2009513712A (ja) | 2005-11-01 | 2009-04-02 | ノバルティス アーゲー | 抗ｃｄ４０抗体の使用 |
| US20100061992A1 (en) * | 2006-11-15 | 2010-03-11 | The Brigham And Women's Hospital, Inc. | Therapeutic uses of tim-3 modulators |
| EP2139923A1 (en) * | 2007-03-28 | 2010-01-06 | Biogen Idec, Inc. | Modulation of tumor microenvironment |
| US20100267934A1 (en) * | 2007-05-31 | 2010-10-21 | Genmab A/S | Stable igg4 antibodies |
| CN104945508B (zh) | 2007-06-18 | 2019-02-22 | 默沙东有限责任公司 | 针对人程序性死亡受体pd-1的抗体 |
| SG10201505369QA (en) | 2007-10-05 | 2015-08-28 | Genentech Inc | Use of anti-amyloid beta antibody in ocular diseases |
| WO2009094273A2 (en) | 2008-01-15 | 2009-07-30 | Yale University | Compositions and methods for adoptive and active immunotherapy |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| WO2010027423A2 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
| AU2009290544B2 (en) | 2008-09-12 | 2015-07-16 | Oxford University Innovation Limited | PD-1 specific antibodies and uses thereof |
| WO2010036959A2 (en) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| AU2009314704A1 (en) * | 2008-11-13 | 2010-05-20 | Instituto De Medicina Molecular | Foxp3+ natural kiler T-cells and the treatment of immune related diseases |
| JP5746040B2 (ja) | 2008-12-03 | 2015-07-08 | ゲンマブ エー／エス | 定常領域の中に改変を有する抗体変種 |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| EP2496594B1 (en) | 2009-11-06 | 2018-01-17 | The J. David Gladstone Institutes | Methods and compositions for modulating tau levels |
| CA2791930A1 (en) * | 2010-03-11 | 2011-09-15 | Kerry Louise Tyson | Pd-1 antibody |
| US8835613B2 (en) | 2010-03-12 | 2014-09-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | β-mannosylceramide and stimulation of NKT cell anti-tumor immunity |
| US10745467B2 (en) * | 2010-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
| US20130323283A1 (en) * | 2010-12-01 | 2013-12-05 | The Children's Hospital Of Philadelphia | Compositions and methods for treating foxp3+ treg related diseases |
| EP3138581B1 (en) | 2011-03-17 | 2019-01-02 | The University of Birmingham | Re-directed immunotherapy |
| EP2688890B1 (en) | 2011-03-22 | 2017-08-30 | Advinus Therapeutics Limited | Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
| CA2830806C (en) | 2011-03-31 | 2020-05-12 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments |
| MX338353B (es) | 2011-04-20 | 2016-04-13 | Medimmune Llc | Anticuerpos y otras moleculas que se unen a b7 - h1 y pd - 1. |
| LT2731677T (lt) * | 2011-07-11 | 2018-07-10 | Glenmark Pharmaceuticals S.A. | Antikūnai, kurie prisiriša prie ox40, ir jų panaudojimas |
| PT2739649T (pt) * | 2011-08-05 | 2018-01-03 | Bioasis Technologies Inc | Fragmentos de p97 com atividade de transferência |
| ES2893855T3 (es) | 2011-08-11 | 2022-02-10 | Ono Pharmaceutical Co | Agente terapéutico para enfermedades autoinmunes que comprende agonista de PD-1 |
| CN104023748B (zh) | 2011-10-28 | 2018-03-02 | 诚信生物公司 | 含有氨基酸的蛋白质制剂 |
| US20150004175A1 (en) | 2011-12-13 | 2015-01-01 | Yale University | Compositions and Methods for Reducing CTL Exhaustion |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| US20150086584A1 (en) | 2012-03-22 | 2015-03-26 | University Of Miami | Multi-specific binding agents |
| EP3144008B1 (en) | 2012-05-08 | 2018-01-17 | The John Hopkins University | Compositions for infusion of transiently engrafting, selected populations of allogeneic lymphocytes |
| NZ622452A (en) | 2012-06-21 | 2017-10-27 | Compugen Ltd | Lsr antibodies, and uses thereof for treatment of cancer |
| US9890215B2 (en) | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
| EP2864352B1 (en) | 2012-06-22 | 2018-08-08 | The Trustees Of Dartmouth College | Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| EP3698809A1 (en) * | 2012-07-31 | 2020-08-26 | The Brigham & Women's Hospital, Inc. | Modulation of the immune response using agents binding tim-3 and ceacam-1 |
| US9783589B2 (en) | 2012-08-13 | 2017-10-10 | Immungene Inc | Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases |
| US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| EP3320914B1 (en) * | 2012-09-10 | 2020-12-30 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | T-helper 1 adjuvant for treating amyotrophic lateral sclerosis |
| EP2897962A1 (en) | 2012-09-21 | 2015-07-29 | Advinus Therapeutics Limited | Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
| US9326999B2 (en) | 2012-10-09 | 2016-05-03 | Sanbio, Inc. | Methods and compositions for treatment of retinal degeneration |
| CA3201072A1 (en) | 2012-10-12 | 2014-04-17 | The Brigham And Women's Hospital, Inc. | Enhancement of the immune response |
| AU2013334610B2 (en) | 2012-10-24 | 2018-09-13 | Novartis Ag | IL-15R alpha forms, cells expressing IL-15R alpha forms, and therapeutic uses of IL-15R alpha and IL-15/IL-15R alpha complexes |
| CN110787285A (zh) | 2012-11-05 | 2020-02-14 | 达纳-法伯癌症研究所股份有限公司 | Xbp1、cd138和cs1肽、包括所述肽的药物组合物及使用所述肽和组合物的方法 |
| WO2014074852A1 (en) | 2012-11-09 | 2014-05-15 | President And Fellows Of Harvard College | Compositions and methods for modulating an immune response |
| US9107960B2 (en) | 2012-12-13 | 2015-08-18 | Immunimedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
| CN105209068A (zh) | 2013-02-07 | 2015-12-30 | 免疫医疗公司 | 用于靶向癌症治疗的缀合至抗体的高效2-吡咯啉多柔比星的前药形式(p2pdox) |
| US9974845B2 (en) | 2013-02-22 | 2018-05-22 | Curevac Ag | Combination of vaccination and inhibition of the PD-1 pathway |
| SG10201707135RA (en) | 2013-03-01 | 2017-10-30 | Astex Pharmaceuticals Inc | Drug combinations |
| ME03470B (me) | 2013-03-13 | 2020-01-20 | Oncoceutics Inc | 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-heksahidroimidazo [1,2-a]pirido[4,3-d]pirimidin-5(3h)-on za upotrebu u liječenju kancera |
| US9376437B2 (en) | 2013-03-13 | 2016-06-28 | Oncoceutics, Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy |
| HUE039473T2 (hu) | 2013-03-14 | 2019-01-28 | Curadev Pharma Private Ltd | Kinurenin útvonal inhibitorok |
| CN111172120A (zh) | 2013-03-14 | 2020-05-19 | 西奈山伊坎医学院 | 新城疫病毒及其用途 |
| US10544187B2 (en) | 2013-03-15 | 2020-01-28 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
| CA2907249A1 (en) | 2013-03-15 | 2014-09-18 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides |
| CA2898126A1 (en) | 2013-03-15 | 2014-09-18 | The Trustees Of The University Of Pennsylvania | Cancer vaccines and methods of treatment using the same |
| AU2014233528B2 (en) | 2013-03-15 | 2019-02-28 | Abbvie Biotherapeutics Inc. | Fc variants |
| CN105431449B (zh) | 2013-04-05 | 2021-08-24 | 港大科桥有限公司 | 新的pd1同种型及其用于加强免疫应答的用途 |
| JP6742903B2 (ja) | 2013-05-02 | 2020-08-19 | アナプティスバイオ インコーポレイティッド | プログラム死−１（ｐｄ−１）に対する抗体 |
| US10260038B2 (en) | 2013-05-10 | 2019-04-16 | Whitehead Institute For Biomedical Research | Protein modification of living cells using sortase |
| CN105683217B (zh) | 2013-05-31 | 2019-12-10 | 索伦托治疗有限公司 | 与pd-1结合的抗原结合蛋白 |
| EP3010528B1 (en) | 2013-06-19 | 2019-09-11 | Massachusetts Institute of Technology | In vivo targeting of cells with ligand-conjugated particles |
| WO2014205194A1 (en) | 2013-06-22 | 2014-12-24 | Nitor Therapeutics | Compositions and methods for potentiating immune response for the treatment of infectious diseases and cancer |
| WO2014209804A1 (en) | 2013-06-24 | 2014-12-31 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
| CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| US9637532B2 (en) | 2013-07-12 | 2017-05-02 | Vlp Therapeutics, Llc | Virus like particle comprising PD-1 antigen or PD-1 ligand antigen |
| KR20220042248A (ko) | 2013-07-16 | 2022-04-04 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 tigit 억제제를 사용한 암을 치료하는 방법 |
| MX2016001555A (es) | 2013-08-08 | 2016-08-03 | Cytune Pharma | Modulocinas basadas en dominio sushi de interleucina-15 (il-15) y receptor alfa de interleucina-15 (il-15ra). |
| AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| KR20160055818A (ko) | 2013-08-22 | 2016-05-18 | 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 | 암 및 바이러스 감염을 치료하기 위한 면역수용체 조절 |
| KR20230085220A (ko) | 2013-08-22 | 2023-06-13 | 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 | 암 및 바이러스 감염을 치료하기 위한 면역수용체 조절 |
| WO2015036394A1 (en) | 2013-09-10 | 2015-03-19 | Medimmune Limited | Antibodies against pd-1 and uses thereof |
| EP3043819A4 (en) * | 2013-09-11 | 2017-04-05 | Compugen Ltd. | Anti-vstm5 antibodies and the use thereof in therapy and diagnosis |
| EP3702373B9 (en) | 2013-09-13 | 2022-11-23 | BeiGene Switzerland GmbH | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
| EP3060251A4 (en) | 2013-10-25 | 2017-12-06 | Pharmacyclics LLC | Treatment using bruton's tyrosine kinase inhibitors and immunotherapy |
| CN104558177B (zh) | 2013-10-25 | 2020-02-18 | 苏州思坦维生物技术股份有限公司 | 拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及其编码序列与用途 |
| GB2519786A (en) | 2013-10-30 | 2015-05-06 | Sergej Michailovic Kiprijanov | Multivalent antigen-binding protein molecules |
| US20150165021A1 (en) | 2013-11-05 | 2015-06-18 | Nkt Therapeutics Inc. | Combination therapy |
| WO2015084721A1 (en) | 2013-12-02 | 2015-06-11 | Tabaczynski David A | Inhibition of isoprenoid biosynthetic pathways to treat autoimmune disorders |
| EP3082802B1 (en) | 2013-12-03 | 2020-02-26 | Iomet Pharma Ltd. | Tryptophan-2,3-dioxygenase (tdo) and/or indolamine-2,3-dioxygenase (ido) inhibitors and their use |
| EA201691078A1 (ru) | 2013-12-06 | 2017-01-30 | Дана-Фарбер Кэнсер Инститьют, Инк. | Терапевтические пептиды |
| CA2932966C (en) | 2013-12-12 | 2022-03-22 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Pd-1 antibody, antigen-binding fragment thereof, and medical use thereof |
| DK3083689T3 (da) | 2013-12-17 | 2020-08-03 | Genentech Inc | Anti-CD3-antistoffer og fremgangsmåder til anvendelse |
| EP3083671B1 (en) | 2013-12-20 | 2020-09-30 | Fred Hutchinson Cancer Research Center | Tagged chimeric effector molecules and receptors thereof |
| WO2015103072A1 (en) | 2013-12-30 | 2015-07-09 | Epimab Biotherapeutics | Fabs-in-tandem immunoglobulin and uses thereof |
| CA3156357A1 (en) | 2014-01-06 | 2015-07-09 | The Trustees Of The University Of Pennsylvania | Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| US10618963B2 (en) * | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| WO2017042633A2 (en) | 2015-09-10 | 2017-03-16 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
| US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
| JP6903432B2 (ja) | 2014-03-12 | 2021-07-14 | イエダ リサーチ アンド ディベロップメント カンパニー リミテッド | Ｃｎｓの疾患および傷害を処置するために全身性調節性ｔ細胞のレベルまたは活性を低下させること |
| CN108135938A (zh) * | 2015-07-16 | 2018-06-08 | 耶达研究及发展有限公司 | 基因修饰的抗第三方中央型记忆t细胞及其在免疫疗法中的用途 |
| EP3341411A1 (en) | 2015-08-28 | 2018-07-04 | Alector LLC | Anti-siglec-7 antibodies and methods of use thereof |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| CA3026477A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 antibodies |
| PT3472207T (pt) | 2016-06-20 | 2021-03-31 | F Star Delta Ltd | Moléculas ligantes que se ligam a pd-l1 e lag-3 |
| EP3571295A1 (en) * | 2017-01-18 | 2019-11-27 | Yeda Research and Development Co. Ltd | Genetically modified veto cells and use of same in immunotherapy |
| EP3911954A4 (en) * | 2019-01-16 | 2022-11-02 | Yeda Research and Development Co. Ltd | BIOMARKERS FOR MODIFICATION OF CNS DISEASES |
| EP3725370A1 (en) * | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
-
2015
- 2015-03-12 JP JP2016556895A patent/JP6903432B2/ja active Active
- 2015-03-12 NZ NZ72500615A patent/NZ725006A/en unknown
- 2015-03-12 US US15/125,249 patent/US10144778B2/en active Active
- 2015-03-12 NZ NZ747418A patent/NZ747418A/en unknown
- 2015-03-12 KR KR1020167028294A patent/KR102248804B1/ko active IP Right Grant
- 2015-03-12 KR KR1020207007068A patent/KR20200029627A/ko not_active IP Right Cessation
- 2015-03-12 KR KR1020237020480A patent/KR20230097209A/ko not_active Application Discontinuation
- 2015-03-12 RU RU2016139974A patent/RU2690670C2/ru active
- 2015-03-12 MX MX2016011832A patent/MX2016011832A/es unknown
- 2015-03-12 WO PCT/IL2015/050265 patent/WO2015136541A2/en active Application Filing
- 2015-03-12 AU AU2015228372A patent/AU2015228372B2/en active Active
- 2015-03-12 CN CN201580024192.2A patent/CN106687125B/zh active Active
- 2015-03-12 CN CN202111374238.7A patent/CN114081946A/zh active Pending
- 2015-03-12 BR BR112016020919A patent/BR112016020919A2/pt not_active Application Discontinuation
- 2015-03-12 EP EP15731728.0A patent/EP3116542A2/en active Pending
- 2015-03-12 CA CA3129892A patent/CA3129892A1/en active Pending
- 2015-03-12 CA CA2942245A patent/CA2942245C/en active Active
- 2015-07-13 US US14/797,894 patent/US9856318B2/en active Active
- 2015-09-10 US US14/850,794 patent/US10214585B2/en active Active
-
2016
- 2016-06-22 US US15/190,160 patent/US9512225B2/en active Active
- 2016-07-05 US US15/202,493 patent/US9512227B2/en active Active
- 2016-07-13 JP JP2018500881A patent/JP6867367B2/ja active Active
- 2016-07-13 AU AU2016293498A patent/AU2016293498B2/en active Active
- 2016-07-13 BR BR112018000646A patent/BR112018000646A2/pt active Search and Examination
- 2016-07-13 KR KR1020187004327A patent/KR20180030128A/ko not_active Application Discontinuation
- 2016-07-13 RU RU2018104962A patent/RU2741366C2/ru active
- 2016-07-13 IL IL256792A patent/IL256792B2/en unknown
- 2016-07-13 MX MX2018000466A patent/MX2018000466A/es unknown
- 2016-07-13 WO PCT/IL2016/050750 patent/WO2017009829A1/en active Application Filing
- 2016-07-13 CA CA2991981A patent/CA2991981A1/en active Pending
- 2016-07-16 US US15/212,231 patent/US9534052B2/en active Active
- 2016-09-11 IL IL247747A patent/IL247747B/en active IP Right Grant
- 2016-09-12 MX MX2021009611A patent/MX2021009611A/es unknown
-
2017
- 2017-11-22 US US15/821,595 patent/US9982048B2/en active Active
- 2017-11-22 US US15/821,603 patent/US9982049B2/en active Active
- 2017-11-22 US US15/821,672 patent/US9982050B2/en active Active
- 2017-11-22 US US15/821,570 patent/US9982047B2/en active Active
- 2017-11-22 US US15/821,678 patent/US9982051B2/en active Active
-
2018
- 2018-08-24 AU AU2018220155A patent/AU2018220155B2/en active Active
- 2018-10-22 US US16/167,226 patent/US10961309B2/en active Active
-
2019
- 2019-02-25 US US16/284,081 patent/US10981989B2/en active Active
- 2019-11-22 JP JP2019210982A patent/JP2020040976A/ja active Pending
-
2020
- 2020-03-04 AU AU2020201602A patent/AU2020201602B2/en active Active
-
2021
- 2021-02-26 US US17/186,960 patent/US11884727B2/en active Active
- 2021-02-26 US US17/187,011 patent/US11884728B2/en active Active
- 2021-04-08 JP JP2021065556A patent/JP2021107412A/ja active Pending
-
2022
- 2022-04-28 AU AU2022202797A patent/AU2022202797A1/en active Pending
- 2022-07-20 JP JP2022115925A patent/JP2022163730A/ja active Pending
-
2023
- 2023-04-12 JP JP2023064537A patent/JP2023089119A/ja active Pending
- 2023-12-11 US US18/535,960 patent/US20240182566A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018524362A5 (lt) | ||
| RU2018104962A (ru) | Снижение системного уровня регуляторных т-клеток или их активности для лечения заболеваний и трамв цнс | |
| KR102023289B1 (ko) | 세포내 항원에 대해 지향된 단일 도메인 항체 | |
| HRP20200652T1 (hr) | Ljudska antitijela na fel d1 i metode njihove primjene | |
| Nguyen et al. | New and emerging therapies for pediatric atopic dermatitis | |
| HRP20200185T1 (hr) | Metode za unaprjeđenje alergen-specifične imunoterapije primjenom inhibitora il-4r | |
| AU2016252038A1 (en) | Inhibitors of immune checkpoint modulators for use in treating cancer and infections | |
| ES2649155T3 (es) | Anticuerpos anti-OX40 y procedimientos de uso de los mismos | |
| Zimmerman et al. | The use of mycophenolate mofetil for the treatment of autoimmune and chronic idiopathic urticaria: experience in 19 patients | |
| RU2019106804A (ru) | Лечение и устойчивая вирусологическая ремиссия при вич-инфекции у haart-стабилизированных пациентов с помощью антител против cd4 | |
| JP2018515474A5 (lt) | ||
| JP2017538671A5 (lt) | ||
| JP2018501197A5 (lt) | ||
| US11723950B2 (en) | CAL-T constructs and uses thereof | |
| JP2018515493A5 (lt) | ||
| JP6918005B2 (ja) | 細胞内抗原に対して向けられた単一ドメイン抗体 | |
| US10555919B2 (en) | Melatonin in autoimmune disease | |
| Pitarokoili et al. | Intrathecal triamcinolone acetonide exerts anti-inflammatory effects on Lewis rat experimental autoimmune neuritis and direct anti-oxidative effects on Schwann cells | |
| JP2020505913A5 (lt) | ||
| Skurkovich et al. | Anticytokine therapy, especially anti‐interferon‐γ, as a pathogenetic treatment in TH‐1 autoimmune diseases | |
| JP2019511226A5 (lt) | ||
| Oki | Eomes-expressing T-helper cells as potential target of therapy in chronic neuroinflammation | |
| RU2017112967A (ru) | Лечение и функциональное излучение вич-инфекции моноклональными антителами к cd4, опосредующими конкуретное ингибирование входа вич | |
| KR20230135556A (ko) | 레트 증후군의 치료를 위한 세마포린-4d 결합 분자의 용도 | |
| JP2016540746A5 (lt) |